Further validation of these transcriptomic findings through mIHF confirmed that, specifically, FAP+αSMA+ CAFs and MYH11+αSMA+ CAFs are linked to poor outcomes in patients with mTLS-positive NSCLC treated with ICIs, suggesting their role in promoting an environment that supports tumor progression and therapy resistance. Here, MYH11 is linked to neoplasm.